Abstracts | ASHG 2019 Annual Meeting 6/4/19, 9(03 PM

Abstract Submission Confirmation -

SAVE THIS MESSAGE
Print This Page

Thank you for submitting an abstract to the ASHG 2019 Annual Meeting in Houston, Texas,
October 15-19! This is confirmation that your abstract has been successfully submitted. You
will receive a separate emailed confirmation/receipt.

Your Abstract Control Number: 1920839

Your Abstract Title: A map of inflammatory-stimulated chromatin in human pancreatic islets reveals novel
mechanisms of type 1 and 2 diabetes risk variants

Please see below for full details of your submission. You may retrieve your submitted abstract at any
time.

If Needed: Revising or Withdrawing Your Abstract

You can go to ASHG Portal to revise or withdraw your abstract. All revisions and withdrawals must be
completed by June 10, 2019 at 11:59 pm U.S. Eastern Time.

Please note: if you need to change the first author of your abstract, you must first withdraw your abstract
and then submit a new abstract with the new name. Abstract submissions are due June 6, 2019 at 11:59
pm U.S. Eastern Time.

Your Next Steps: Registration, Travel, and Hotel

https://www.ashg.org/cgi-bin/2019/abs19a/absa.pl Page 1 of 4
Abstracts | ASHG 2019 Annual Meeting 6/4/19, 9(03 PM

Registration: Please register as soon as possible and take advantage of discounted rates. Do not wait
until you receive your program confirmation before registering. Submission of an abstract does NOT
automatically register you for the meeting.

International attendees: We urge those who require visas to register now and begin the visa application
process, which can take up to 6 months. Further details on this process are available online.
Download your customized letter of invitation to ASHG 2019 Annual Meeting, which may be
needed for your visa application.

Hotel reservations: Please make your hotel reservations as soon as possible to ensure you receive
the hotel of your choice. If you need to change your arrival/departure dates, you will be able to do so.

Abstract Control Number: 1920839

Abstract was submitted on 2019-06-05 00:02:20 (U.S. east coast time)

Name & Address:
Anthony Aylward , BS or BA
Bioinformatics & Systems Biology
University of California San Diego
San Diego, CA 92122
United States
Phone: 530-774-6697
Email: aaylward@eng.ucsd.edu
Presenting Author Status (when attend the meeting in October): Graduate Student
Trainee Research Award Application: None
Presentation Preference: Plenary/Platform talk or Poster
Abstract Topic Choice:
Main Topic Choice: 7. Epigenetics and Gene Regulation
Subtopic: D. Diabetes, Obesity, and Metabolic Syndromes
Keywords: 45 56 76 95 168
Track (that my abstract best fits in): Basic
Authors:
A. Aylward1,2, M. Okino2, P. Benaglio2, J. Chiou2,3, E. Beebe2, S. Huang2, A. Padilla2, K.J. Gaulton2
Institutions:
1) Bioinformatics & Systems Biology, University of California San Diego, San Diego, CA.; 2) Pediatrics,
University of California San Diego, San Diego, CA.; 3) Biomedical Science, University of California San
Diego, San Diego, CA.
Title:

https://www.ashg.org/cgi-bin/2019/abs19a/absa.pl Page 2 of 4
Abstracts | ASHG 2019 Annual Meeting 6/4/19, 9(03 PM

A map of inflammatory-stimulated chromatin in human pancreatic islets reveals novel mechanisms of

type 1 and 2 diabetes risk variants
Abstract:
The majority of genetic risk loci for type 1 and type 2 diabetes (T1D, T2D) occupy non-coding DNA
and affect gene regulation in disease-relevant tissues such as pancreatic islets. Islets occupy a
complex and dynamic microenvironment, and the responses of islets to environmental changes during
diabetes progression are important mediators of disease etiology. Currently available epigenomic maps,
however, do not effectively capture changes in the chromatin landscape of islets upon exposure to
disease-relevant environmental conditions. In this study we used ATAC-seq and RNA-seq to map
chromatin accessibility and gene expression from a total of 7 primary human islet samples exposed to
pro- and anti-inflammatory treatment conditions relevant to diabetes pathophysiology, including
glucocorticoids (dexamethasone) and cytokines (IL-1β, IFNγ, TNF-α) in multiple combinations and
concentrations. We identified highly dose- and stimulus-dependent changes in chromatin accessibility
in stimulated compared to untreated islets that mapped to 4,193 stimulus-responsive sites, transcription
factor motifs driving these changes such as IRF/STAT for cytokines and glucocorticoid receptor
(GR/NR3C1) for dexamethasone, and target genes and molecular pathways affected by stimulus-
responsive chromatin. A majority of stimulus-responsive sites (3,643/87%) had evidence for differential
chromatin accessibility on a gradient across glucocorticoid-treated, untreated and cytokine-treated
islets. We observed enrichment of genetic variants influencing diabetes risk within stimulus-responsive
islet chromatin, and identified fine-mapped diabetes risk variants in stimulus-responsive chromatin
including at the SIX3 and NFATC2 loci. At NFATC2, rs3787186 is likely causal for both T1D and T2D
risk, mapped in an islet chromatin site with a gradient of activity across stimuli, had stimulus-dependent
allelic effects on islet chromatin in allelic imbalance and gene reporter assays, altered a binding motif
for GR and other nuclear hormone receptors, was linked to the NFATC2 promoter using single cell co-
accessibility, and affected NFATC2 expression in islet eQTLs. Our results provide an expanded catalog
of chromatin sites in pancreatic islets upon exposure to diverse, disease-relevant environmental
conditions through which we identify a greater breadth of genetic mechanisms and genes underlying
diabetes risk.

Publication Status:
The work outlined in this abstract Has not been published elsewhere.
The work outlined in this abstract Has not been accepted for future publication.
Relationship(s) to Disclose: No
I intend to discuss unlabeled/off-label use of FDA-approved product(s): No
I intend to discuss investigational product(s) (not FDA-approved): No
If you have included a table in your abstract, it may not appear to be accurately formatted on this
confirmation (due to possible wrapping). It is important that you email a copy of any table, formatted as
you wish it to appear, to ashgmeetings@ashg.org by June 10. Be sure to include your name as first
author, the title of your abstract, the abstract control number, and your email address.

What Happens Now: Abstract Review and Programming

https://www.ashg.org/cgi-bin/2019/abs19a/absa.pl Page 3 of 4
Abstracts | ASHG 2019 Annual Meeting 6/4/19, 9(03 PM

After the submission deadline, all abstracts will be reviewed by the 2019 Program Committee and
independent reviewers. Program assignment for platform and poster presentations will be available in
mid-August. The Annual Meeting website will include searchable scientific abstracts along with an
individualized meeting itinerary planner.
Abstract FAQs
How Abstracts are Reviewed, Programmed, and Published

Later: Submit Your Work to AJHG

Please consider submitting your work to ASHG’s journal,

The American Journal of Human Genetics. AJHG welcomes submissions of
articles and reports on timely subjects concerning all aspects of the genetics of
humans. AJHG provides rapid publication in a Society Journal with a long-standing
reputation for high quality. Publication by ASHG members is free of charge, and
trainee member first authors are eligible for the annual Cotterman Awards.

Additional Information

ASHG 2019 Annual Meeting Website

ASHG Web Portal — renew your membership, change your address, view previous meeting
webcasts, and more!
Questions or comments? Email ashgmeetings@ashg.org.

https://www.ashg.org/cgi-bin/2019/abs19a/absa.pl Page 4 of 4